ArticleFrontiers in pharmacology2022

CXCR2 Small-Molecule Antagonist Combats Chemoresistance and Enhances Immunotherapy in Triple-Negative Breast Cancer.

Alaa M Ghallab et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.